Original Shark, Kevin Harrington, Vouches For Psychedelics Through Psycheceutical
Famed entrepreneur Kevin Harrington thrives in the realm of possibility. Inventors have come to him with the equivalent of a sketch on a napkin seeking guidance and investment. It’s his uncanny ability to imagine what could be rather than what already is that has brought Harrington, and those he deems fit, tremendous success. Now, he has his sights set on the psychedelics industry.
After some shopping around (fitting for the man who created the infomercial), he landed on Psycheceutical, Inc. (a wholly-owned subsidiary of Psycheceutical Bioscience, Inc. (OTC: BWVI), a biopharmaceutical company dedicated to the development and commercialization of psychedelic medicines.
Harrington joins Psycheceutical to provide expertise on the strategy, direction, and execution of the company’s growth and development in pursuit of its mission to accelerate the research, availability, and delivery of safer and more effective psychedelic pharmaceutical medicines.
He tells The Dales Report that he believes psychedelics is a trillion-dollar industry.
As an original shark on the hit TV show Shark Tank and pioneer of the As Seen on TV brand, Kevin Harrington’s business ventures have launched more than 1,000 products and produced well over $6 billion in global sales. More than 20 of Harrington’s companies have each topped $100 million in revenue.
When he looked at the fundamentals of Psycheceutical, beyond the appeal of Zappy Zapolin serving as Chief Visionary Officer, the company enticed him because of its patented technology and dosing systems. They are capable of creating their own products, as well as employing a “coopetition” model (cooperation x competition) to license their delivery systems to other companies.
“There are a lot of people who need help. Psycheceutical will be pushing to bring these medicines to the marketplace. There will, of course, be tests and government approvals, but when products work and there is a problem in the marketplace, generally, there is a way to speed things up,” says Harrington, speaking to his role as strategic advisor. “I believe the world of psychedelic medicine is needed and will be very powerful for magical transformations.”
About Psycheceutical, Inc.
Psycheceutical, Inc. is the wholly-owned subsidiary of Psycheceutical Bioscience, Inc. (OTC: BWVI). Powered by a team with more than 100 years’ combined experience in development, regulatory approval processes, and commercialization across the pharmaceutical industry, Psycheceutical is on a mission to accelerate the research, availability, and delivery of safer and more effective psychedelic pharmaceutical medicines. Learn more at Psycheceutical.com.
